Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry

被引:44
作者
Al-Quran, Samer Z. [1 ]
Yang, Lijun
Magill, James M.
Braylan, Rau C.
Douglas-Nikitin, Vonda K. [2 ]
机构
[1] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA
[2] William Beaumont Hosp, Royal Oak, MI 48072 USA
关键词
CD138; multiple myeloma; bone marrow; smears; plasma cell count;
D O I
10.1016/j.humpath.2007.04.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Assessment of bone marrow involvement by malignant plasma cells is an important element in the diagnosis and follow-up of patients with multiple myeloma and other plasma cell dyscrasias. Microscope-based differential counts of bone marrow aspirates are used as the primary method to evaluate bone marrow plasma cell percentages. However, multiple myeloma is often a focal process, a fact that impacts the accuracy and reliability of the results of bone marrow plasma cell percentages obtained by differential counts of bone marrow aspirate smears. Moreover, the interobserver and intraobserver reproducibility of counting bone marrow plasma cells microscopically has not been adequately tested. CD138 allows excellent assessment of plasma cell numbers and distribution in bone marrow biopsies. We compared estimates of plasma cell percentages in bone marrow aspirates and in hematoxylin-eosin- and CD138-stained bone marrow biopsy sections (CD138 sections) in 79 bone marrows from patients with multiple myeloma. There was a notable discrepancy in bone marrow plasma cell percentages Using the different methods of observation. In particular, there was a relatively poor concordance of plasma cell percentage estimation between aspirate smears and CD138 sections. Estimates of plasma cell percentage using CD138 sections demonstrated the highest interobserver concordance. This observation was supported by computer-assisted image analysis. In addition, CD 138 expression highlighted patterns of plasma cell infiltration indicative of neoplasia even in the absence of plasmacytosis. We conclude that examination of CD138 sections should be considered for routine use in the estimation of plasma cell load in the bone marrow. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1779 / 1787
页数:9
相关论文
共 35 条
[1]   BONE-MARROW HISTOLOGY IN MYELOMA - ITS IMPORTANCE IN DIAGNOSIS, PROGNOSIS, CLASSIFICATION AND STAGING [J].
BARTL, R ;
FRISCH, B ;
BURKHARDT, R ;
FATEHMOGHADAM, A ;
MAHL, G ;
GIERSTER, P ;
SUND, M ;
KETTNER, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (03) :361-375
[2]   HISTOLOGIC CLASSIFICATION AND STAGING OF MULTIPLE-MYELOMA - A RETROSPECTIVE AND PROSPECTIVE-STUDY OF 674 CASES [J].
BARTL, R ;
FRISCH, B ;
FATEHMOGHADAM, A ;
KETTNER, G ;
JAEGER, K ;
SOMMERFELD, W .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (03) :342-355
[3]   Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions [J].
Bayer-Garner, IB ;
Sanderson, RD ;
Dhodapkar, MV ;
Owens, RB ;
Wilson, CS .
MODERN PATHOLOGY, 2001, 14 (10) :1052-1058
[4]  
BUSS D H, 1987, Hematologic Pathology, V1, P35
[5]  
Chilosi M, 1999, MODERN PATHOL, V12, P1101
[6]   The Mi15 monoclonal antibody (anti-Syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens [J].
Costes, V ;
Magen, V ;
Legouffe, E ;
Durand, L ;
Baldet, P ;
Rossi, JF ;
Klein, B ;
Brochier, J .
HUMAN PATHOLOGY, 1999, 30 (12) :1405-1411
[7]   Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation [J].
Dhodapkar, MV ;
Abe, E ;
Theus, A ;
Lacy, M ;
Langford, JK ;
Barlogie, B ;
Sanderson, RD .
BLOOD, 1998, 91 (08) :2679-2688
[8]   Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment [J].
Dhodapkar, MV ;
Sanderson, RD .
LEUKEMIA & LYMPHOMA, 1999, 34 (1-2) :35-43
[9]   Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells [J].
Jego, G ;
Robillard, N ;
Puthier, D ;
Amiot, M ;
Accard, F ;
Pineau, D ;
Harousseau, JL ;
Bataille, R ;
Pellat-Deceunynck, C .
BLOOD, 1999, 94 (02) :701-712
[10]  
Kyle RA, 2003, BRIT J HAEMATOL, V121, P749